Navigation Links
New therapy prevents dangerous side effect for lymphoma patients
Date:12/9/2008

SAN FRANCISCO - Patients respond well to a new three-drug combination for indolent B cell lymphoma that also spares them prolonged, potentially lethal, suppression of blood production in the bone marrow, researchers at The University of Texas M. D. Anderson Cancer Center report today at the 50th annual meeting of the American Society of Hematology.

Pentostatin, cyclophosphamide and rituximab together are providing the same remission rate as other combinations but with minimal long-term bone marrow suppression, said study presenter Felipe Samaniego, M.D., associate professor in M. D. Anderson's Department of Lymphoma and Melanoma.

Myelosuppression leads to production of fewer red blood cells, white blood cells and platelets. When prolonged, it can lead to myelodysplastic syndrome, which comprises several conditions that cause potentially lethal insufficient blood production.

"The worst outcome of long-term myelosuppression for indolent B cell lymphoma patients is myelodysplastic syndrome," Samaniego said. "In this study, out of 80 patients, none developed MDS."

And 77 of 80 (96 percent) experienced either complete remission or unconfirmed complete remission. Some did have low blood counts, but all were short-term. Overall, the combination is well-tolerated, the research team reported.

Prolonged myelosuppression also makes treatment much more difficult if a patient's lymphoma recurs, Samaniego said. "Patients treated with myelosuppressing agents have a difficult time tolerating another round of chemotherapy if their lymphoma comes back."

Indolent B cell lymphomas comprise follicular lymphoma, small lymphocytic lymphoma, and marginal zone lymphoma. These slow-growing but potentially lethal cancers are the most common form of non-Hodgkin lymphoma.

Samaniego and colleagues have been testing new drug combinations against indolent B cell lymphoma that reduce myelosuppression.

Two years ago, a combination of fludarabine, mitoxantrone and dexamethasone with rituximab and interferon alpha reduced the incidence of MDS to 4 percent of patients, down from a historical rate of around 10 percent.

The key ingredient in pushing the MDS rate to zero, Samaniego says, was substitution of fludarabine with pentostatin. Both are nucleoside analogs, which interfere with DNA reproduction, and target lymphoid cells, making them attractive drugs for lymphomas.

Earlier research indicated that pentostatin is less toxic to bone marrow than other members of this drug class.

"The PCR combination is a very promising therapy for indolent B cell lymphoma," Samaniego said.


'/>"/>

Contact: Scott Merville
smerville@mdanderson.org
713-792-0661
University of Texas M. D. Anderson Cancer Center
Source:Eurekalert  

Related medicine news :

1. Intense chemotherapy wards off recurrence in half of mantle cell lymphoma patients after seven years
2. Statin Use Doesnt Inhibit Lymphoma Drug Therapy
3. Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkins Lymphoma
4. 33rd Annual Hutch Holiday Gala Raises Millions for Cancer Immunotherapy Research
5. Lenalidomide safe as single therapy for elderly CLL patients
6. Amylin, Lilly Update on FDA Review of BYETTA(R) (exenatide) Injection Monotherapy Submission
7. The St. John-Clark Pain Treatment Center Forms Manual Therapy 'Dream Team'
8. Aggressive Therapy May Stem CF Progression in Infants
9. Washington State Health Care Authority to Launch Medication Therapy Management Initiative
10. MaxCyte to Present Targeted Cancer Immunotherapy Product at 50th Annual Meeting of the American Society of Hematology
11. Oncologists Rank Aloxis Marketing Message Most Influential in the Chemotherapy-Induced Nausea and Vomiting Drug Market
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
New therapy prevents dangerous side effect for lymphoma patients
(Date:12/2/2016)... Phoenix (PRWEB) , ... December 02, 2016 , ... ... statewide documentary on the perils of heroin that was watched live by 1 ... national Alfred I. duPont-Columbia University Award. , ASU students at the Walter Cronkite ...
(Date:12/2/2016)... ... ... Advanced Inc., a leading provider of travel therapy and travel nursing across ... Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. Jason previously served as Vice ... leadership experience to Advanced Inc. He began his career in finance at Ernst & ...
(Date:12/2/2016)... ... December 02, 2016 , ... U.S. Surgeon General, Dr. Vivek Murthy, graces ... explains how he was inspired to practice medicine at an early age by his ... more than making diagnoses and prescribing medicine,” he states. “It is about building relationships ...
(Date:12/2/2016)... ... 2016 , ... More than half of American teens report losing their virginity ... with their child about sex related topics, less than 60 percent spoke about deeper ... announce the launch of its second edition of the “Sexual Wellness” campaign, aiming to ...
(Date:12/2/2016)... ... December 02, 2016 , ... Universal Medical Systems, Inc. ... the first company to offer robotic imaging to veterinary medicine is sponsoring the ... 941 for the American Association of Equine Practitioners 62nd Annual Convention from December ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... Lianluo Smart Limited (Nasdaq: ... develops, markets and sells medical devices and wearable ... and international markets, recently attended the 2016 ... Progress Forum, co-hosted by the Institute of Interventional ... Guangdong Provincial People,s Hospital and Cardiology Department of ...
(Date:12/2/2016)... 2, 2016 On Thursday, the NASDAQ ... Dow Jones Industrial Average edged 0.36% higher, to finish at ... Losses were broad based as six out of nine sectors ... reports on the following Services equities: Myriad Genetics Inc. (NASDAQ: ... ), INC Research Holdings Inc. (NASDAQ: INCR ), ...
(Date:12/2/2016)... Conn. , Dec. 1, 2016  Today, Simpson ... announced the honor of being selected as winners of ... Simpson Healthcare Executives Website at the PLATINUM level, Blue ... Training Module at the GOLD Level, and our proprietary ... At Simpson Healthcare Executives, we are excited to ...
Breaking Medicine Technology: